Invitrogen Corporation and RXi Pharmaceuticals Corporation have entered into an agreement whereby RXi will exclusively license second generation RNA interference (RNAi) technology from Invitrogen for designated target genes in all human therapeutic categories.
Invitrogen’s patent applications that are part of this agreement cover Stealth™ and other proprietary technologies related to enhanced configurations of chemically modified double-stranded RNA. Terms of the agreement were not disclosed.
“Licensing this broad technology from Invitrogen is part of our strategy to continually enhance our proprietary rxRNA™ compounds for therapeutic applications,” said Dr. Tod Woolf, President and Chief Executive Officer of RXi.
“Currently Invitrogen Stealth™ RNAi synthetic duplexes are widely used for RNAi research across both in vitro and in vivo applications due to their specificity, efficacy and stability,” said Amy Butler, Invitrogen vice president of gene expression profiling.
“We see the use of our Stealth™ RNAi technology in therapeutics as a natural next step in Invitrogen’s efforts to be at the cutting edge of in vivo gene regulation.”